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Drs Huddleston and Choongdoi:10.1016/j.jtcvs.2004.07.058Objective: In patients with severe pulmonary hypertension associated with con-
genital heart disease, we prefer to perform repair of the congenital heart disease and
lung transplantation whenever feasible so as to augment the donor pool and avoid the
cardiac complications associated with heart transplantation. We report our experience
with repair of congenital heart disease and lung transplantation and compare the results
with those of patients who underwent heart-lung transplantation during the same period.
Methods: The records of patients who had repair of congenital heart disease and
lung transplantation (n  35) and heart-lung transplantation (n  16) between 1990
and 2003 were reviewed.
Results: The underlying congenital heart disease in the repair of congenital heart
disease and lung transplantation group included transposition of great vessels (n
 2), atrioventricular canal defect (n  2), ventricular septal defect (n  9),
pulmonary venous obstruction (n  7), scimitar syndrome (n  2), pulmonary
arterial atresia or stenosis (n  5), and others (n  8). Thirteen of the patients
undergoing repair of congenital heart disease and lung transplantation (37.1%)
had the congenital heart disease repaired before lung transplantation; the re-
maining congenital heart disease repairs were performed concurrently with
transplantation. Sixteen patients underwent heart-lung transplantation because
of poor left ventricular function or single-ventricle anatomy. Freedoms from
bronchiolitis obliterans at 1, 3, and 5 years were 72.9%, 54.7%, and 54.7% for
the repair of congenital heart disease and lung transplantation group and 77.8%,
51.9%, and 38.9% for the heart-lung transplantation group, respectively. Sur-
vivals at 1, 3, and 5 years were 62.9%, 51.4%, and 51.4% for the repair of
congenital heart disease and lung transplantation group and 66.5%, 66.5%, and
60% for the heart-lung transplantation group, respectively.
Conclusion: Repair of congenital heart disease and lung transplantation is a
feasible treatment option. Long-term outcome is determined by associated
complications related to lung transplantation. Despite the complexity of com-
bined congenital heart disease repair with lung transplantation and the resulting
perioperative morbidity, the patients had similar outcomes to those of patients
who underwent heart-lung transplantation.
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TXTreatment options for patients with severepulmonary hypertension associated withcongenital heart disease (CHD) include acombined repair of the underlying congeni-tal heart lesion and lung transplantation(CCLT) or heart-lung transplantation (HLT).
In patients with a correctable congenital cardiac lesion, we
prefer to perform CCLT to preserve the native heart, avoid
the long waiting times for heart-lung grafts, and avoid the
cardiac complications associated with heart transplantation.
We report our experience with CCLT and compare the
results with those of patients who underwent HLT at this
center during the same period.
Methods
Patients
Between July 1990 and September 2003, a total of 274 pediatric
lung transplantation procedures were performed at St Louis Chil-
dren’s Hospital. During this time, 35 children underwent CCLT
and 16 children underwent HLT. These two groups of patients
form the basis of this report (Table 1).
Pretransplantation Diagnosis
Patients in the CCLT group had a heterogeneous group of correct-
able congenital lesions (Table 2). The diagnoses can be divided
into four categories. The first category included patients with types
of CHD known to lead to the early development of pulmonary
hypertension. These included congenital pulmonary venous steno-
sis, scimitar syndrome, and uncorrected ventricular septal defect.
The second category included patients who acquired pulmonary
hypertension at an earlier date than would be expected on the basis
of the CHD. An example from this group is onset of pulmonary
hypertension in patients with an atrial septal defect. Children in the
third category had pulmonary hypertension despite early and ad-
equate correction of CHD (atrial septal defect or ventricular septal
defect). The fourth category of patients had pulmonary hyperten-
sion in association with a functionally inadequate vascular bed.
These lesions included tetralogy of Fallot, multiple peripheral
pulmonary arterial stenosis, and pulmonary arteriovenous malfor-
mations. The HLT group included patients with pulmonary hyper-
tension who also had congenital cardiac lesions that were consid-
ered uncorrectable, either on the basis of the underlying anatomy
(eg, single-ventricle anatomy or physiology) or because of unsuc-
cessful attempts at correction, patients unlikely to have a success-
ful repair of the lesion, and patients with severely depressed left
ventricular function (Table 2).
Pretransplantation Evaluation
All other organ systems were evaluated to assess viability before
listing for transplantation. Patients were excluded from listing if
there was evidence of serious irreversible organ injury. In addition,
social circumstances were carefully investigated including a frank
discussion with the parents regarding commitment and risks in-
volved in the therapy. Mechanical ventilation or extracorporeal
membrane oxygenation (ECMO) support were not considered ab-
solute contraindications to transplantation. A major issue pertain-
ing to the consideration for lung transplantation was whether there
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tension. In some cases, patients were treated with prolonged
courses of epoprostenol and/or inotropic agents. Lung transplan-
tation was undertaken only when we were certain that the pulmo-
nary hypertension was irreversible.
Transplant Technique
The bilateral sequential lung transplantation and HLT procedures
were performed with techniques previously described.1,2 The ap-
proach was through a bilateral anterolateral transsternal (clam-
shell) thoracotomy incision for patients undergoing bilateral lung
transplantation, an anterolateral thoracotomy that extended across
the sternum into the contralateral chest for those undergoing sin-
gle-lung transplantation, and a median sternotomy for those un-
dergoing HLT.3 Cardiopulmonary bypass was used in all in-
stances. In the CCLT group, bilateral sequential lung transplant
technique was used in 30 patients, and single-whole lung trans-
plantation was performed in 5 patients. When a cardiac lesion was
to be repaired, this was done after bilateral recipient pneumonec-
tomy with the heart arrested. This provided a completely bloodless
field to allow rapid repair of the intracardiac lesion.
Immunosuppression
“Triple drug” (cyclosporine [INN: ciclosporin], azathioprine, and
steroids) immunosuppression was used. For the first posttransplan-
tation year, the target trough cyclosporine blood level was 300 to
350 ng/mL; subsequent trough target levels were 200 to 300
ng/mL. The initial steroid dose was 0.5 mg/kg daily for pred-
nisone. The steroid dose was progressively tapered with time to as
low as 0.1 mg/kg every other day, but we do not believe it is
appropriate to stop this drug entirely. An azathioprine dose of 1 to
2 mg/kg daily was administered as long as the patient’s white
blood cell count exceeded 3500 cells/mm3. All patients received
prophylaxis against Pneumocystis carinii pneumonia either as sul-
famethoxazole and trimethoprim three times per week (orally) or
as monthly treatment with aerosolized pentamidine when sulfa
allergy or intolerance was present. Prophylaxis against mucocuta-
neous candidal infections was also given. Patients at risk for
cytomegalovirus infection received ganciclovir prophylaxis.
Posttransplantation Surveillance
Surveillance after lung transplantation was performed with fre-
quent spirometry and serial bronchoscopy with biopsy and bron-
choalveolar lavage. Bronchoscopy was performed at regular inter-
vals after transplantation: at 2 weeks, 1 month, 2 months, and
3 months, and then every 3 months thereafter. Transbronchial
biopsy was performed at these intervals and at any time there was
a change in clinical status for which rejection was a plausible
explanation. The technique of transbronchial biopsy performed in
infants has been described.4,5 When tissue sampling was inade-
quate, and a change in clinical status persisted, open lung biopsy
was performed. Full pulmonary function measurements were per-
formed at the same intervals as for bronchoscopy. Children
younger than 5 years are generally not able to fully cooperate for
standard pulmonary function tests. They were therefore evaluated
with infant pulmonary function tests performed with standard
techniques.6,7 The diagnosis of bronchiolitis obliterans is more
difficult in small infants because they are not able to perform
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bronchiolitis obliterans syndrome as defined by Cooper and col-
leagues.8 We used information from infant pulmonary function
tests to assess for a fall of 50% in the ratio of specific flow at
functional reserve capacity to functional reserve capacity per ki-
logram in the absence of other pathologic processes as a diagnosis
of bronchiolitis obliterans.9 Open lung biopsy was undertaken to
confirm or deny this diagnosis.
Statistics
Normally distributed continuous data are expressed as mean 
SD. Medians with ranges are used when continuous data are
skewed. Categoric data are expressed as counts and proportions.
Unrelated two-group comparisons were performed with paired,
2-tailed t tests for means of normally distributed continuous
variables and the Wilcoxon rank sum test for skewed data.
Fisher exact or 2 tests were used to analyze differences in
proportions among the categoric data. Kaplan-Meier estimate
was used to depict survival and freedom from obliterative
bronchiolitis. Survival and bronchiolitis obliterans–free sur-
vival comparisons between groups of patients were completed
with the Mantel-Haenszel log-rank test. All data analysis was
performed with the SPSS software package (SPSS 11.0 for
Windows; SPSS Inc, Chicago, Ill).
Results
Deaths on the Waiting List
Seventeen patients with pulmonary hypertension and CHD
died while on the waiting list. Six of these were waiting for
HLT, and the other 11 were to undergo CCLT. Five of the
11 awaiting CCLT were infants with pulmonary vein ste-
nosis. The average time to death while awaiting lung trans-
plantation in this group was 16 days, underscoring the
critical nature of this diagnosis in the very young patients.
Two other children with this diagnosis were seen later in life
with unilateral pulmonary vein stenosis and died after 211
and 323 days on the waiting list. Although we generally
view children with Eisenmenger syndrome with an unre-
paired ventricular septal defect as being in relatively stable
condition, 3 of the 11 children with this diagnosis died while
awaiting CCLT. Excluding 1 patient listed for longer than
TABLE 1. Demographic characteristics and pretransplanta
Age at transplantation (y, median and interquartile range)
Sex (No. female)
Hemodynamic values
Mean pulmonary arterial pressure (mm Hg, mean SD)
Cardiac index (L/[min · m2], mean SD)
Pulmonary vascular resistance (Wood units, mean SD)
Requirement of ECMO support at transplantation (No.)
Requirement of mechanical ventilation at transplantation (No.)
Time on waiting list (d, mean SD)5 years, the average times from listing to death in the CCLT
The Journal of Thoraciand HLT groups were 162 and 125 days, respectively. The
timing of referral would obviously have a major impact on
these data.
Pretransplantation Data
The demographic and pretransplantation data of both CCLT
and HLT groups are shown in Table 1. The underlying CHD
diagnoses in both groups are shown in Table 2. The age
distributions of patients in both groups are depicted in
Figure 1. Pulmonary hypertension in both groups was man-
aged with a combination of nitric oxide, epoprostenol, and
inotropic agents. The difference in average age at transplan-
tation between the two groups is related those undergoing
CCLT for pulmonary venous obstruction, primarily infants
younger than 1 year. There was a significant difference in
time on the waiting list for the two groups, with the CCLT
group waiting approximately a third as long as the HLT
group. This is a reflection of both difficulty in acquiring an
adequate heart-lung block for those patients undergoing
HLT and the younger age of those undergoing CCLT. More
patients in the CCLT group were on life-support devices, a
reflection of our reluctance to accept patients for HLT
whose condition had deteriorated to the point of requiring
evaluation
CCLT (n  35) HLT (n  16) P value
1.7 (0.7-11.4) 14.8 (11.8-17.0) .001
18 (51.4%) 10 (62.5%) .384
66.2 10.6 68.4 18.7 .621
2.4  0.6 2.3  0.8 .499
21.2 6.8 30.1 11.2 .008
4 (11.4%) 1 (6.3%) .999
11 (31.4%) 1 (6.3%) .075
150.2 290.6 453.3 402.5 .013
TABLE 2. Diagnoses for transplantation
No.
CCLT (n  35)
Ventricular septal defect 9
Pulmonary venous obstruction 7
Pulmonary artery atresia or stenosis 5
Atrioventricular canal defect 2
Transposition of great arteries 2
Scimitar syndrome 2
Others 8
HLT (n  16)
Single-ventricle anatomy or uncorrectable cardiac lesion 11
Severely depressed left ventricular function 5tionmechanical ventilation or ECMO.
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Thirteen of the patients in the CCLT group (37.1%) under-
went CHD repair before lung transplantation, whereas the
remaining CHD repairs were performed concurrently with
lung transplantation. Eleven patients in the HLT group
underwent cardiothoracic procedures before HLT. In the
CCLT group, 30 patients underwent bilateral sequential
lung transplantation, and the remaining 5 had single whole-
lung transplantation. The mean cardiopulmonary bypass
times for CCLT and HLT groups were 187 58 and 224
Figure 1. Age distribution
TABLE 3. Outcomes after transplantation
Early
Requirement for posttransplantation ECMO support (No.)
Reexploration for bleeding (No.)
Coagulopathy (No.)
Vascular stenosis requiring dilatation or revision (No.)
Airway complication (No.)
Cardiac arrest (No.)
Duration of mechanical ventilation (d, median and IQR)
Stay in pediatric intensive care unit (d, median and IQR)
Hospital stay (d, median and IQR)
In-hospital deaths (No.)
1990–1995
1996–2003
Late
Diagnosis of post-transplant lymphoproliferative disease (No.)
Requirement for retransplantation (No.)
Coronary artery disease (No.)
IQR, Interquartile range.127 minutes, respectively (P  .161).
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The early and late outcomes after surgery are shown in
Table 3. Three of the 5 patients who required ECMO
support at the time of transplantation had successful wean-
ing from ECMO and did not require further support after
surgery. The remaining 2 patients, 1 each in the CCLT and
HLT groups, required ongoing ECMO support after trans-
plantation. Seven additional patients required ECMO sup-
port after transplantation, and these 9 patients were unable
to be weaned from ECMO despite maximal medical ther-
CCLT and HLT recipients.
CCLT (n  35) HLT (n  16) P value
5 (14.3%) 4 (25.0%) .436
16 (45.7%) 7 (43.8%) .762
8 (22.9%) 3 (18.8%) .999
5 (14.3%) 0 .248
6 (17.1%) 0 .159
4 (11.4%) 1 (6.3%) .999
14 (3–33) 2 (2–6) .007
18 (6–28) 5 (3–8) .006
30 (15–47) 15 (10–19) .010
9 (25.7%) 5 (31.3%) .999
7/22 (32%) 4/8 (50%)
2/13 (15%) 1/8 (13%)
5 (14.3%) 1 (6.3%) .999
3 (8.6 %) 2 (12.5%) .643
0 1 (6.3%) .999apy. All 9 patients (5 CCLT and 4 HLT) died in the
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patients was generally quite complex. There was a high
incidence of reexploration for bleeding in each group. Be-
yond that, the patients in the CCLT group were ventilated
longer and stayed longer in the pediatric intensive care unit
than those in the HLT group. Five of the patients in the
CCLT group required stenting of either a pulmonary artery
or pulmonary venous anastomotic stricture. There are no
pulmonary vascular anastomoses in HLT, and this compli-
cation therefore did not occur in that group. Six of the
patients in the CCLT group had airway strictures develop
that required dilatation or stenting. None of the tracheal
anastomoses in the HLT group developed complications.
Survival
Overall hospital survival for the CCLT group was 74%, and
that for the HLT group was 69%. The causes of in-hospital
deaths in the CCLT group were graft failure in 5 patients,
severe intraoperative hemorrhage in 2 patients, and infec-
tion in 2 patients. Causes of 10 late deaths in the CCLT
group were bronchiolitis obliterans in 3 patients, infection
in 5 patients, and malignancy in 2 patients. Causes of 5
in-hospital deaths in the HLT group (31.3%) were graft
failure in 2 patients, severe intraoperative hemorrhage in 2
patients, and infection in 1 patient. Causes of 2 late deaths
in the HLT group were cardiac arrest related to coronary
arteriopathy in 1 patient and infection in the other patient.
The Kaplan-Meier survivals at 1, 3, and 5 years were
62.9%, 51.4%, and 51.4%, for the CCLT group and 66.5%,
66.5%, and 60% for the HLT group, respectively (Figure 2).
There was an improvement in in-hospital mortality in the
period of 1996 to 2003 relative to our earlier experience
from 1990 to 1995 (Table 3). This was primarily related to
better patient selection because we recognized the very high
risk of bleeding in cyanotic patients who have had previous
Figure 2. Kaplan-Meier survivals after transplantation stratified
by CCLT and HLT.lateral thoracotomy incisions.
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At a median follow-up of 2.7 years (interquartile range 54
days–7.1 years), 14 patients in the CCLT group and 6
patients in the HLT group had developed bronchiolitis ob-
literans. Kaplan-Meier freedoms from bronchiolitis obliter-
ans at 1, 3, and 5 years were 72.9%, 54.7%, and 54.7% for
the CCLT group and 77.8%, 51.9%, and 38.9% for the HLT
group, respectively (Figure 3). There was no statistically
significant difference between the two groups (P  .442).
Other late outcomes are shown in Table 3. The cardiac
repair was successful in most cases, except for 3 patients.
One patient had residual mild to moderate mitral regurgita-
tion after a mitral valve repair that had remained stable on
follow-up. Another patient was found to have a residual
patent ductus arteriosus after surgical ligation, and this was
successfully occluded with coils. Another patient developed
moderate aortic regurgitation after an arterial switch oper-
ation for the treatment of transposition of great arteries. This
patient died of a severe viral infection and septicemia. These
postoperative cardiac repair complications were not directly
responsible for any late deaths.
Discussion
CHD is currently the most common indication for lung
transplantation in children younger than 1 year.10 Among
pediatric lung transplants performed between January 1991
and June 2002, as registered with the International Society
of Heart and Lung Transplantation (ISHLT), it accounted
for 48.8% of the indications in children younger than 1 year,
11.6% of the indications in younger children aged 1 to 10
years, and 3% of the indications in children aged 11 to 17
years. We previously reported our early experience in the
treatment of children with CHD and pulmonary hyperten-
sion.3,11 This report forms a comprehensive update of our
experience and long-term follow-up.
The patients in this report had various types of CHD in
association with pulmonary hypertension. Patients in the
Figure 3. Kaplan-Meier freedoms from bronchiolitis obliterans
(BOS) after transplantation stratified by CCLT and HLT.CCLT group can be divided into four clinical categories as
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ventricle anatomy or physiology associated with pulmonary
hypertension, an uncorrectable cardiac lesion associated
with pulmonary hypertension, or poor left ventricular func-
tion associated with pulmonary hypertension. In some pa-
tients, the relationship between the CHD and the develop-
ment of secondary pulmonary hypertension was expected,
such as in patients with a large, uncorrected ventricular
septal defect. On the other hand, other patients had associ-
ated pulmonary hypertension without an obvious cause,
such as patients with a functionally inadequate pulmonary
vascular bed. These patients may have had pulmonary hy-
pertension similar to primary pulmonary hypertension.
Children with pulmonary hypertension in association with
CHD therefore comprise a heterogeneous group of pa-
tients.12,13
The initial approach to patients with CHD and pulmo-
nary hypertension was HLT.14 Repair of congenital cardiac
lesion and lung transplantation was first reported by Fremes
and associates15 in 1990. Subsequently, other cases were
reported in the literature.16-18 Our practice has been to
perform repair of congenital cardiac lesion if the lesion is
correctable with relatively straightforward standard tech-
niques. One must recognize that a complex repair requiring
prolonged myocardial ischemia will result in elevation of
the left ventricular end-diastolic pressure and subject the
newly transplanted lungs to pulmonary edema. Thus we
would caution against any procedure resulting in myocar-
dial ischemic times in excess of 60 minutes.
The patients in the CCLT group were clearly different
from those in the HLT group in that the former group
consisted of patients who had correctable congenital cardiac
lesions. Treatment was tailored to repair the congenital
lesion and perform lung transplantation for the treatment of
pulmonary hypertension. In contrast, HLT was in general
reserved for patients with pulmonary vascular disease in
association with an uncorrectable congenital cardiac lesion,
single-ventricle anatomy or physiology, or severely de-
pressed left ventricular function. Although we have com-
pared the two groups, they include quite different patients,
even given the common theme of CHD and pulmonary
hypertension. We approach all patients with this combina-
tion initially looking at the feasibility of lung transplantation
alone with repair of the cardiac lesion. Only those not
deemed appropriate for that approach are listed for HLT.
There are several advantages of CCLT relative to HLT.
These include preservation of the native heart, shorter wait-
ing time for donor lungs than for a heart-lung block, aug-
mentation of the donor pool by allowing the another donor
heart to be placed for a potential cardiac recipient, and
avoidance of complications associated with cardiac trans-
plantation. HLT has the advantages of replacing a structur-
ally abnormal heart with a normal heart and the relative
666 The Journal of Thoracic and Cardiovascular Surgery ● Marsimplicity of the operation itself. HLT has the disadvantages
of complications associated with cardiac transplantation, as
seen in a patient in the HLT group who died of transplant
coronary vasculopathy. Although the number of patients in
the pediatric registry is too small to analyze, in the adult
population of patients undergoing HLT, transplant coronary
vasculopathy accounts for 5% to 10% of all late deaths.
Approximately 1 in 6 organ donors has lungs suitable for
donation. Thus not every potential cardiac donor will have
suitable lungs for transplantation. Donor hearts are allocated
to status 1A heart transplant recipients, ahead of patients
awaiting heart-lung blocks. The average waiting time for
donor lungs in the CCLT group was 150 days, whereas there
was a markedly longer waiting time (average of 453 days)
for HLT blocks. The overall survival of children undergoing
HLT has been worse than that of those undergoing lung
transplantation alone, as noted in the Registry for the
ISHLT.10 Perhaps in view of these reasons, the number of
pediatric HLTs performed as registered with the ISHLT has
continued to decrease through 2001, and the overall number
performed worldwide in 2001 was approximately 10. The
ISHLT registry showed that the number of infant and child
HLT recipients has decreased to negligible numbers, and
even the number of adolescent recipients has decreased with
time.10
Right single-lung transplantation was performed in 3 of
the 5 patients in our initial experience.3 Early reports had
suggested that single-lung transplantation might be applica-
ble to the very young patient, with satisfactory relief of
pulmonary hypertension and maintenance of good cardiac
function.19 Bilateral lung transplantation, however, has been
our preferred technique since 1993. We have preferred
bilateral lung transplantation because we hope that it will
provide the maximum possible pulmonary vascular bed and
alveolar volume for continued lung growth and develop-
ment.3,9,20 The ISHLT data have shown that bilateral lung
transplantation is associated with an improved survival after
single-lung transplants for pediatric recipients.10 In the
CCLT group, 5 patients underwent single-lung transplanta-
tion early in our program, whereas the remainder underwent
bilateral lung transplantation.
The patients in the CCLT group were younger and ap-
peared to be a sicker cohort of patients, with about a third
requiring preoperative mechanical ventilation and 11.4%
requiring ECMO support. Their postoperative course was
also more complicated, with a longer stay in the intensive
care unit and a longer overall hospital stay than in the HLT
group. After transplantation, however, the two groups of
patients had similar in-hospital mortalities, with primary
lung graft failure as the predominant cause of death. Among
the hospital survivors, patients from the CCLT and HLT
groups had similar freedoms from bronchiolitis obliterans
and survival. None of the patients in the CCLT group died
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to the repaired congenital cardiac lesion. After transplanta-
tion, we observed that most morbidity and mortality was
related to complications of transplantation, such as primary
donor lung graft failure, infection, neoplasms, and bronchi-
olitis obliterans. It is seen that repair of congenital lesion in
the CCLT group was feasible and did not cause any long
term morbidity or mortality. The survival after hospital
discharge and incidence of bronchiolitis obliterans were
similar to a group of patients undergoing lung transplanta-
tion at St Louis Children’s Hospital for other indications.
The ISHLT results have also shown that the causes of death
after pediatric HLT are comparable to those seen after lung
transplantation, with graft failure accounting for 50% of
deaths within 30 days; after 1 year, bronchiolitis obliterans
accounted for approximately 50% of deaths.10
The in-hospital mortality dropped significantly in both
groups in a later era relative to our early experience. That is
most likely attributable to better candidate selection. We
recognized early on that the adhesions after thoracotomies
in patients with cyanosis and pulmonary hypertension were
extraordinarily vascular and dense. These adhesions are
quite different from those observed in patients with cystic
fibrosis who have had previous thoracotomies. Arterial col-
lateral vessels arising from the intercostals, internal tho-
racic, and axillary arteries penetrate into the lung paren-
chyma to provide more pulmonary blood flow. These
vessels become large and are quite difficult to control during
the recipient pneumonectomies. This results in considerable
blood loss, longer time on cardiopulmonary bypass, post-
transplantation reexploration, hemodynamic instability, and
transfusion with multiple blood products. All contribute to
the risk of early graft dysfunction.
In summary, this article reviews our experience with two
treatment strategies available for the treatment of a hetero-
geneous group of patients with CHD. CCLT was used for
patients with correctable congenital cardiac lesions,
whereas HLT was used when the CHD lesion was not
amenable to repair. Both CCLT and HLT are feasible sur-
gical treatment strategies, and the in-hospital mortalities
have markedly improved with time. Despite the complexity
of performing a combined congenital cardiac lesion repair
with lung transplantation and the resulting increased peri-
operative morbidity, the patients had an in-hospital mortal-
ity and long-term outcomes similar to those of patients who
underwent HLT. Early and long-term outcomes were deter-
mined by associated complications related to lung trans-
plantation. We conclude that for patients who require lung
transplantation for pulmonary hypertension associated with
CHD, correction of the cardiac lesion should be undertaken
when possible to avoid the potential disadvantages and
complications associated with HLT.
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Discussion
Dr Vaughn A. Starnes (Los Angeles, Calif). This report reviews
the outcomes of 51 infants, children, and adolescents treated for
CHD and pulmonary hypertension. Thirty-five children were
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might add that this experience was extracted from a very large
pediatric lung transplantation experience of more than 274 pa-
tients. So this group has selected a very demanding population of
patients. As clearly outlined in the article, HLT is becoming, or
already has become, a treatment option that is not available be-
cause of the limited donor pool. Therefore this experience with
CCLT is increasingly important for this group of children with
Eisenmenger physiology. I have several questions, Dr Huddleston.
Which congenital heart defects were repaired before transplanta-
tion, and why? You report that about 20% of these patients had
some kind of previous repair. Was that a palliative repair that led
to repair of the heart defect, and then transplantation?
Dr Huddleston. This was a very complicated group of patients
because of a variety of diagnoses and treatment. Among the CCLT
group of patients who had a previous repair, half of those patients
had a palliative operation while the other half had a corrective
operation of the congenital heart defect. The 2 patients with
transposition of the great arteries who underwent transplantation
had undergone an arterial switch during infancy, at an appropriate
time, within the first week after birth, but had persistent and
progressive pulmonary hypertension, and went on to transplanta-
tion because of that.
Dr Starnes. There was a large group of these children with
airway or vascular complications. I would assume that those were
in the younger age group. If so, are there any technical points that
you can share with us that might improve the outcome? You had
a very large group of infants with pulmonary vein stenosis. Is there
anything that you can impart to us, such as absorbable sutures,
running suture lines, or anything that you could tell us?
Dr Huddleston. We use absorbable suture for all the anasto-
moses in the first place. The airway problems were distributed
throughout the age groups. They were not concentrated in the
infants. As for the pulmonary vascular anastomotic complications,
arterial stenoses occurred only in the left pulmonary artery. I think
the reason, at least in part, is that the left pulmonary artery in these
patients is oriented in a more posterior direction than in a normal
setting. I don’t have a good explanation for that, but in the patients
who had left pulmonary artery stenosis or near occlusion after
transplantation, the angiograms show this somewhat oblique take-
off at the anastomosis from the native pulmonary artery. So what
we started to do to counteract that was to take the anastomosis
almost to the main pulmonary artery and not put it out further onto
the left pulmonary artery. So that would be my suggestion, and is
what we’ve done to try to avoid the arterial anastomotic problem.
Dr Starnes. Just one further technical issue. In these small
children, the phrenic nerve is close to pulmonary venous cuffs.
And I noticed that there was a lengthy time on the ventilator for
some of these children. Was that related to phrenic nerve injury, or
was it just a graft issue?
Dr Huddleston. In this case it was almost all graft issues. No
phrenic nerve issues kept these children on the ventilator.
Dr Starnes. With a limited donor pool of pediatric lungs, we
need to decide on the best recipient. Do we put the lung in a child
with a congenital heart lesion that we’re going to repair, or do we
put it into another child? On the basis of your experience, do you
have any thoughts about that? Are there some patients who should
not undergo this therapy?
668 The Journal of Thoracic and Cardiovascular Surgery ● MarDr Huddleston. I believe that patients who have had previous
thoracotomies probably should not undergo transplantation in this
setting. The collateral vessels that develop in this situation, as I’m
sure all of you know, can be enormous, and can produce formi-
dable bleeding during lysis of adhesions. A previous sternotomy
would not preclude transplantation, but certainly a previous tho-
racotomy incision should be an absolute contraindication.
Dr Thomas L. Spray (Philadelphia, Pa). This is a nice sum-
mary of a long experience. I have a couple of brief questions.
What you’ve shown here is that there are two groups of
patients, one young relative to the other, and yet the incidences of
bronchiolitis obliterans were similar out to the length of follow-up.
Like the report from the larger experience at Washington Univer-
sity presented at this meeting a couple of days ago, there was no
real difference in the incidence of bronchiolitis obliterans, and yet
one was a relatively young patient population (a mean age of 1.5
years) and the other was a relatively older population (mean age of
14.7 years).
Some previous reports have suggested that the younger patients
have a relatively more beneficial course in terms of bronchiolitis
obliterans. Are you backing away from that? Do you believe that
that’s really the case, that younger patients have a preferential
immune status in lung transplantation as they do in heart trans-
plantation, or do you think that this ongoing experience now is
evening out some of that observed difference?
Dr Huddleston. That’s a good question. The real advantage,
immunologically, that we’ve seen in terms of looking at acute
rejection in bronchiolitis obliterans has been in the even younger
age group, that is, those 6 months old or younger. The group of
patients undergoing transplantation in that age range have been
primarily those with congenital lung diseases, rather than, say,
pulmonary vein stenosis, which comprises a large portion of the
infant population in this report. So no, we’re not backing away
from that notion, but pushing the age further toward the neonatal
period to say whether the advantage immunologically arises.
Dr Spray. Second, you had two groups, one spanning about a
5-year period and the other spanning about an 8-year period. And
in the second group, which was 1996 to 2003, the number of
patients undergoing CCLT was lower than in the first group, which
spanned a shorter period. You suggested that you’ve changed your
selection criteria, and maybe that accounts for some of the differ-
ence. What kinds of changes have you made in your selection
criteria? Has it just been in terms of thoracotomy and bleeding
issues, or are there other more subtle changes in your selection
criteria that account for the decrease in number more recently?
Dr Huddleston. It has been because we’ve really stayed away
from the kids that have had previous thoracotomies. I think that’s
really been the main issue that we’ve addressed, trying to stay
away from that patient population.
Dr Spray. Thoracotomy with or without cyanosis, or do you
think it matters?
Dr Huddleston. Well, they virtually all have cyanosis.
Dr Spray. The patients with pulmonary vein stenosis have
cyanosis?
Dr Huddleston. None of those have had previous thoracoto-
mies, in general.
Dr Marshall L. Jacobs (Philadelphia, Pa). Dr Huddleston,compliments on managing this incredibly challenging group of
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attrition while awaiting transplantation for both groups. Obviously,
for the infants with pulmonary vein problems and so on, you have
very little choice in terms of timing. After mentioning the waiting
list deaths, you advised transplantation for these patients before
they get too sick.
How would this experience affect your advice to cardiologists
and families of adolescent patients who are exercise limited but in
relatively stable condition with Eisenmenger physiology from car-
diac lesions associated with left-to-right shunt? Is there an optimal
time for referral, or does one wait until there is hemoptysis,
arrhythmias, and morbid events?
Dr Huddleston. That’s a good question. I think for the typical
patient with Eisenmenger syndrome, such as a patient with a
ventricular septal defect, these patients can live for a long time.
Now, we did have some in our group that, for whatever reason, had
progressive disease and required transplantation to avoid death.
Most of those deaths were patients with more complicated disease
than just that. Pulmonary vein stenosis actually made up a fairly
large percentage. Single-ventricle anatomy, complicated single
ventricles that had failed palliative operations (Glenn shunt, etc),
were in that group as well.
So my focus would be on pulmonary vein stenosis or lesions in
that area that are a problem. Historically, there’s been some
reluctance to go after the pulmonary veins primarily with some of
the operations that the Toronto group has described. And when I
get called about these kids now, I always encourage the referring
center to do those operations, to approach it like that, because of
this problem with deaths while on the waiting list.
Dr Jacobs. So in reality, given the fact that organs gets allo-
cated to the most severely ill patients, is there really, at this time,
limited application of this therapy to a patient with a ventricular
The Journal of Thoraciseptal defect and Eisenmenger syndrome? Are those becoming a
very small group?
Dr Huddleston. Well, organs aren’t allocated according to
severity of illness for lungs or heart-lung blocks. That’s only for
other organ transplant groups. So it’s first come, first served for
lungs.
Dr Jacobs. Well, the patient between the teens and the third
decade of life, who is functionally limited but not morbidly ill with
Eisenmenger syndrome from a ventricular septal defect or from
untreated truncus arteriosus, are some of those patients included in
this group? And at what time do you refer those patients for
transplantation?
Dr Huddleston. Those patients come to transplantation when
they have heart failure in conjunction with their cyanosis. We
really try to tease out the ones who have a very limited survival,
recognizing that it is difficult, and also, even with some heart
failure you can live for a long, long time. So we try to identify
those who are really at the end stage.
Dr Gary K. Lofland (Kansas City, Mo). I just want to con-
gratulate you and your colleagues on a courageous undertaking
and a beautiful presentation. I do have one technical question,
which may be addressed in the article. Do you think that some of
the difference in pretransplantation pulmonary vascular resistance
between the two groups could be attributable to the difficulty
inherent in accurately calculating pulmonary vascular resistance in
a single-ventricle population? We encounter that in our Fontan
population.
Dr Huddleston. I think that’s probably right, in that it was very
difficult to get at those numbers.
I would like to thank Dr Spray for his many contributions to the
development of this program in the first place back in the early
1990s.
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